Future directions for peptide therapeutics development
Top Cited Papers
- 30 September 2013
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 18 (17-18), 807-817
- https://doi.org/10.1016/j.drudis.2013.05.011
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 ReceptorExperimental Diabetes Research, 2012
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in MonotherapyDiabetes Care, 2012
- Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptorNature Communications, 2012
- The potential for NX-1207 in benign prostatic hyperplasia: an update for cliniciansTherapeutic Advances in Chronic Disease, 2011
- Lixisenatide: evidence for its potential use in the treatment of type 2 diabetesCore Evidence, 2011
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologiesJournal of Experimental & Clinical Cancer Research, 2010
- Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeuticProceedings of the National Academy of Sciences of the United States of America, 2010
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and BenefitsDiabetes Care, 2010
- Contemporary strategies for the stabilization of peptides in the α-helical conformationCurrent Opinion in Chemical Biology, 2008